we pursue class action and individual cases in a variety of practice areas


Case Name: In re: Aggrenox Antitrust Litigation

Docket No.: 3:14-md-02516


filed:November 20, 2013

court:U.S. District Court, District of Connecticut

The Aggrenox case was filed on November 20, 2013 and has been consolidated before the District of Connecticut. Aggrenox is a extended-release capsule of dipyridamole indicated to lower the risk of stroke in people who have had transient ischemic attack or stroke due to blood clot.

The Aggrenox complaint alleges that defendants’ entered into an anticompetitive “pay for delay” agreement that is delaying for seven years any lower priced generic equivalent from entering the market and forcing consumers and health plans to artificially inflated prices for the drug.